Optimizing Outcomes of Treatment-Resistant Depression in Older Adults

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Collaborators: National Institute of Mental Health (NIMH); Patient-Centered Outcomes Research Institute
• Treatments: Antidepressive Agents; Aripiprazole; Bupropion; Lithium Carbonate; Nortriptyline

Criteria

Inclusion Criteria:

• Men and women aged 60 and older

• Current Major Depressive Disorder (MDD)

• Failure to respond adequately to two or more antidepressant treatment trials of recommended dose and length

• Patient Health Questionnaire-9 (PHQ-9) score of 10 or higher

Exclusion Criteria:

• Inability to provide informed consent

• Dementia

• Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms

• High risk for suicide and unable to be managed safely in the clinical trial

• Contraindication to proposed study medications, as determined by study physician including history of intolerance or non-response to proposed medications.

• Non-correctable, clinically significant sensory impairment interfering with participation

• Unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cerebrovascular or cardiovascular risk factors that are not under medical management.

• Moderate to severe substance or alcohol use disorder